Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines

Journal of Medicinal Chemistry

Volumn 42, Issue 5, 1999, Pages 833-848

  Chorvat, Robert J ^a   Bakthavatchalam, Rajagopal ^a   Beck, James P ^a   Gilligan, Paul J ^a   Wilde, Richard G ^a   Cocuzza, Anthony J ^a   Hobbs, Frank W ^a   Cheeseman, Robert S ^a   Curry, Matthew ^a   Rescinito, Joseph P ^a   Krenitsky, Paul ^a   Chidester, Dennis ^a   Yarem, Jerry A ^a   Klaczkiewicz, John D ^a   Hodge, C Nicholas ^a   Aldrich, Paul E ^a   Wasserman, Zelda R ^a   Fernandez, Christine H ^a   Zaczek, Robert ^a   Fitzgerald, Lawrence W ^a   Huang, Shiew Mei ^a,b   Shen, Helen L ^a   Wong, Y Nancy ^a,c   Chien, Ben M ^a   Quon, Check Y ^a   Arvanitis, Argyrios ^a   more..

^a DUPONT COMPANY   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; IMIDAZOPYRIDINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYCLIZATION; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONFORMATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; INTRAVENOUS DRUG ADMINISTRATION; LIPOPHILICITY; METHYLATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE; DOGS; HUMANS; MICE; PYRIDINES; PYRIMIDINES; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033545628     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980224g     Document Type: Article

References (32)

1. Bakthavatchalam, R.; Aldrich, P. E.; Arvanitis, A. G.; Beck, J. P.; Calabrese, J. C.; Cheeseman, R. S.; Chorvat, R. J.; et al. Novel Imidazolo and Triazolopyrimidine Derivatives as Corticotropin-Releasing Hormone (CRH) Antagonists. 212th National Meeting of the American Chemical Society, Aug 25-29, 1996; MEDI 093.
2. Rivier, C.; Vale, W. Modulation of stress-induced ACTH release by corticotropin releasing factor, catecholamines and vasopressin. Nature (London) 1983, 305, 325-327.
3. Vale, W.; Spiess, J.; Rivier, C.; Rivier, J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981, 213, 1394-1397.
4. Vale, W.; Rivier, C.; Brown, M. R.; Spiess, J.; Koob, G.; Swanson, L.; Bilezikjian, L.; Bloom, F.; Rivier, J. Chemical and biological characterization of corticotropin-releasing factor. Recent Prog. Horm. Res. 1983, 39, 245-270.
5. Koob, G. F.; Bloom, F. E. Corticotropin-releasing factor and behavior. Fed. Proc. 1985, 44, 259-263.
6. DeSouza, E. B.; Insel, T. R.; Perrin, M. H.; Rivier, J.; Vale, W. W.; Kuhar, M. J. Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J. Neurosci. 1985, 5, 3189-3203.
7. Owens, M. J.; Nemeroff, C. B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 1991, 43 (4), 425-473.
8. Blalock, J. E. A molecular basis for bidirectional communication between the immune and neuroendocrine systems. Physiol. Rev. 1989, 69, 1-32.
9. Irwin, M. Stress-induced immune suppression: Role of brain corticotropin releasing horone and autonomic nervous system mechanisms; Elsevier Science Ltd.: New York, 1994, Vol. 4, pp 29-47.
10. Sapolsky, R. M. Hypercortisolism among socially subordinate wild baboons originates at the CNS level. Arch. Gen. Psychiatry 1989, 46, 1047-1051.
11. Arvanitis, A. G.; et al. Non-peptide corticotropin-releasing hormone antagonists: Syntheses and structure - activity relationships of 2-anilinopyrimidines and -triazines. J. Med. Chem. 1999, 42, 805-818.
12. Dunn, J. J.; Berridge, C. W. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res. Rev. 1990, 15, 71-100.
13. Owens, M. J.; Overstreet, D. H.; Knight, D. L.; Rezvani, A. H.; Ritchie, J. C.; Bissette, G.; Janowsky, D. S.; Nemeroff, C. B. Alterations in the hypothalamic-pituitary-adrenal axis in a proposed animal model of depression with genetic muscarinic supersensitivity. Neuropsychopharmacology 1991, 4 (2), 87-93.
14. Britton, D. R.; Koob, G. F.; Rivier, J.; Vale, W. Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci. 1982, 31, 363-367.
15. Berridge, C. W.; Dunn, A. J. Corticotropin-releasing factor elicits naloxone sensitive stress-like alterations in exploratory behavior in mice. Regul. Pept. 1986, 16, 83-93.
16. Berridge, C. W.; Dunn, A. J. A corticotropin-releasing factor antagonist reverses the stress-induced changes in exploratory behavior appear to be mediated by norepinephrine-stimulated release of CRF. Hormon. Behav. 1987, 21, 393-401.
17. Owens, M. J.; Vargas, M. A.; Nemeroff, C. B. The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: implications for a role for CRF in the pathogenesis of anxiety disorders. J. Psychiatr. Res. 1993, 27 (Suppl. 1), 209-220.
18. Koob, G. F.; Britton, K. T. Behavioral effects of corticotropin-releasing factor. Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide; DeSouza, E. B., Nemeroff, C. B., Eds.; CRC Press: Boca Raton, FL, 1990; pp 253-266.
19. Swerdlow, N. R.; Geyer, M. A.; Vale, W. W.; Koob, G. F. Corticotropin-releasing factor potentiates acoustic stratle in rats: blockade by chlorodiazepoxide. Psychopharmacology 1986, 88, 147-152.
20. Britton, K. T.; Lee, G.; Koob, G. F. Corticotropin releasing factor and amphetamine exaggerate partial agonist properties of benzodiazepine antagonist Ro 15-1788 in the conflict test. Psychopharmacology (Berlin) 1988, 94 (3), 306-311.
21. Grigoriadis, D. E. Characterization of Corticotropin-releasing Factor Receptor Subtypes. Ann. N. Y. Acad. Sci. 1996, 780.
22. Hodge, C. N., P. Aldrich, C. Fernandez, R. Chorvat, R. Cheeseman, T. Christos, A. Arvanitis, E. Scholfield, P. Krenitsky, P. Gilligan, E. Ciganek, P. Strucely, Z. Wasserman, Novel CRF Antagonist Design Guided by Ligand Conformational Studies. 212th National Meeting of the American Chemical Society, Aug 25-29, 1996; MEDI 094.
23. Hodge, C. N.; et al. Corticotropin-releasing hormone receptor antagonists: Framework design and synthesis guided by ligand conformational studies. J. Med. Chem. 1999, 42, 819-832.
24. Schulz, D. W.; Mansbach, R. S.; J.E.A. Sprouse, CP-154,526: A potent and selective nonpeptide antagonist of corticotrophin releasing factor receptors. Proc. Natl. Acad. Sci. 1996, 93, 10477-10482.
25. Albert, A., D. J. Brown, H. C. S. Wood, Pteridine Studies. Part V. The Monosubstituted Pteridines. J. Chem. Soc. 1954, 3832.
26. Chen, Y. L. Pyrrolopyrimidines as CRF antagonists. World Patent Appl. WO 9413676-A1, 1994.
27. Chen, Y. L. Pyrazolopyrimidines as CRF antagonists. World Patent Appl. WO 9413677-A1, 1994.
28. Pardridge, W. M. Transport of small molecules through the blood-brain barrier: biology and methodology. Adv. Drug Delivery Rev. 1995, 15, 5-36.
29. Hansch, C., J. P. Bjorkroth, A. Leo, Hydrophobicity and Central Nervous System Agents: On the Principle of Minimal Hydrophobocity In Drug Design. J. Pharm. Sci. 1987, 76 (9), 663-687.
30. Rekker, R. F. The Hydrophobic Fragment Constant; Elsevier: New York, 1977.
31. Mansbach, R.; Brooks, E. N.; Chen, Y. L. Antidepressant-like effects of CP-154.526, a selective CRF1 receptor antagonist. Eur. J. Pharmacol. 1997, 323, 21-26.
32. Shen, H.-S. L., N. Wong, S. G. Culp, H. Zeng, J. Yarem, R. Bakthavatchalam, T. E. Christos, A. J. Cocuzza, B. M. Chien, L. Lian, P. Saxton, C. Y. Quon, S.-M. Huang, Pharmacokinetics of a series of corticotropin-releasing factor (CRF) receptor antagonists in rats and dogs. 11th AAPS National Meeting, Seattle, WA, 1996.